| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1368-7646(03)00060-8 |
| P698 | PubMed publication ID | 12962683 |
| P50 | author | Barbara Ensoli | Q21255143 |
| Cecilia Sgadari | Q38546658 | ||
| Paolo Monini | Q38546673 | ||
| P2093 | author name string | Elena Toschi | |
| Giovanni Barillari | |||
| P2860 | cites work | Aids-related malignancies | Q22251046 |
| Angiogenesis in cancer and other diseases | Q27861015 | ||
| Matrix metalloproteinases | Q28140451 | ||
| Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3 | Q28144040 | ||
| Rational design of peptide-based HIV proteinase inhibitors | Q28330897 | ||
| A phase II trial of marimastat in advanced pancreatic cancer | Q28366568 | ||
| In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors | Q28368771 | ||
| Generation and degradation of human endostatin proteins by various proteinases | Q28610281 | ||
| Matrix Metalloproteinase Inhibitors and Cancer--Trials and Tribulations | Q29544430 | ||
| New functions for the matrix metalloproteinases in cancer progression | Q29547738 | ||
| Tumor targeting with a selective gelatinase inhibitor | Q30747366 | ||
| Mechanism of paclitaxel activity in Kaposi's sarcoma. | Q31397250 | ||
| Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis | Q31643030 | ||
| Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention | Q33606833 | ||
| Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel | Q33824632 | ||
| Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults | Q33925343 | ||
| Activation of matrix-metalloproteinase-2 and membrane-type-1-matrix-metalloproteinase in endothelial cells and induction of vascular permeability in vivo by human immunodeficiency virus-1 Tat protein and basic fibroblast growth factor | Q33948194 | ||
| Block of AIDS-Kaposi's sarcoma (KS) cell growth, angiogenesis, and lesion formation in nude mice by antisense oligonucleotide targeting basic fibroblast growth factor. A novel strategy for the therapy of KS. | Q34155667 | ||
| Biology of Kaposi's sarcoma | Q34292002 | ||
| Clinical aspects and management of AIDS-related Kaposi's sarcoma | Q34292020 | ||
| Reactivation and role of HHV-8 in Kaposi's sarcoma initiation | Q34295807 | ||
| Management of Kaposi sarcoma: the role of interferon and thalidomide | Q34368769 | ||
| Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials | Q34461569 | ||
| Angiogenic effects of extracellular human immunodeficiency virus type 1 Tat protein and its role in the pathogenesis of AIDS-associated Kaposi's sarcoma | Q34587184 | ||
| Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. | Q34749386 | ||
| Matrix metalloproteinases (MMPs) regulate fibrin-invasive activity via MT1-MMP-dependent and -independent processes | Q36369835 | ||
| Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial | Q36644664 | ||
| Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study | Q36800955 | ||
| Successful treatment of cutaneous Kaposi's sarcoma by the 585-nm pulsed dye laser | Q36889366 | ||
| Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-Infected patients receiving highly active an | Q39682736 | ||
| HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells | Q40697876 | ||
| HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma | Q40747284 | ||
| Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors | Q40851323 | ||
| Binding of active (57 kDa) membrane type 1-matrix metalloproteinase (MT1-MMP) to tissue inhibitor of metalloproteinase (TIMP)-2 regulates MT1-MMP processing and pro-MMP-2 activation. | Q40886684 | ||
| Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma | Q41435232 | ||
| Effects of angiogenesis inhibitors on multistage carcinogenesis in mice | Q41648802 | ||
| Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma | Q41719276 | ||
| HIV-protease inhibitors | Q41751665 | ||
| The mechanism of insulin resistance caused by HIV protease inhibitor therapy. | Q42802122 | ||
| The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance | Q42828632 | ||
| Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study | Q43469561 | ||
| Clinical assessment of HIV-associated lipodystrophy in an ambulatory population | Q43706991 | ||
| Differential effects of HIV-1 protease inhibitors on dendritic cell immunophenotype and function | Q43767922 | ||
| The human 26S proteasome is a target of antiretroviral agents. | Q43966362 | ||
| The HIV protease inhibitor ritonavir increases lipoprotein production and has no effect on lipoprotein clearance in mice. | Q44138786 | ||
| Early reduction of immune activation in lymphoid tissue following highly active HIV therapy | Q44178152 | ||
| Angiogenic potential in vivo by Kaposi's sarcoma cell-free supernatants and HIV-1 tat product: inhibition of KS-like lesions by tissue inhibitor of metalloproteinase-2. | Q44213622 | ||
| Can antiviral agents decrease the occurrence of Kaposi's sarcoma? Clinical Epidemiology Group from Centres d'Information et de Soins de l'Immunodéficience Humaine | Q44882356 | ||
| Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans | Q46083258 | ||
| HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. | Q48965078 | ||
| Early effects of antiretroviral combination therapy on activation, apoptosis and regeneration of T cells in HIV-1-infected children and adolescents. | Q52033611 | ||
| NK cell activity controls human herpesvirus 8 latent infection and is restored upon highly active antiretroviral therapy in AIDS patients with regressing Kaposi's sarcoma. | Q53957330 | ||
| Concentration-targeted therapy and the future of HIV management. | Q53969659 | ||
| Highly active antiretroviral therapy inhibits cytokine production in HIV-uninfected subjects | Q57716722 | ||
| Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome | Q58276496 | ||
| Tumor invasion: molecular shears blunted by green tea | Q58906570 | ||
| Changes in thymic function with age and during the treatment of HIV infection | Q59066353 | ||
| Serum Concentrations of Fibroblast Growth Factor 2 Are Increased in HIV Type 1-Infected Patients and Inversely Related to Survival Probability | Q60194030 | ||
| Radiotherapy for Kaposi's sarcoma | Q71494346 | ||
| Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease | Q73470103 | ||
| Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy | Q74165679 | ||
| Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma | Q74628317 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 173-181 | |
| P577 | publication date | 2003-08-01 | |
| P1433 | published in | Drug Resistance Updates | Q3040081 |
| P1476 | title | HIV protease inhibitors as new treatment options for Kaposi's sarcoma | |
| P478 | volume | 6 |
| Q39426973 | Abnormalities in alternative splicing of angiogenesis-related genes and their role in HIV-related cancers |
| Q33321331 | Alterations in the Notch4 pathway in cerebral endothelial cells by the HIV aspartyl protease inhibitor, nelfinavir |
| Q46770167 | Indinavir influences biological function of dendritic cells and stimulates antifungal immunity. |
| Q36563576 | The impact of highly active antiretroviral therapy on the incidence and outcomes of AIDS-defining cancers in Southern Alberta |
Search more.